Lately, there has been an increased incidence of late stent thrombosis; especially following Drug eluting stent (DES) implantation. Several factors are associated with an increased risk of stent thrombosis, including the procedure itself, patient and lesion characteristics, stent design, and premature cessation of anti-platelet drugs. We present a case of late stent thrombosis (LST) following DES implantation after a period of 68 months, making it the longest reported case of LST reported in the literature, despite the use of dual anti-platelet therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844360 | PMC |
| http://dx.doi.org/10.1186/1757-1626-3-68 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of the prognostic performance of TIMI, PAMI, CADILLAC and GRACE scores for short-term major adverse cardiovascular events in patients undergoing emergent percutaneous revascularisation: a prospective observational study.
BMJ Open
March 2025
National Institute of Cardiovascular Diseases, Karachi, Pakistan.
Objectives: Accurately predicting short-term MACE (major adverse cardiac events) following primary percutaneous coronary intervention (PCI) remains a clinical challenge. This study aims to assess the effectiveness of four established risk scores in predicting short-term MACE after primary PCI.
Design: Prospective observational study.
Pediatric living donor liver transplantation for small infants with biliary atresia using interposition portal vein grafts, multi-center cohort study.
Liver Transpl
March 2025
Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.
Background: Despite multiple techniques, portal vein (PV) inflow reconstruction during living donor liver transplantation (LDLT) for patients with biliary atresia (BA) and small-diameter PV remains a challenge. The use of PV interposition grafts has emerged as a promising therapeutic strategy to mitigate complications and reinterventions.
Methods: We conducted a retrospective multi-center cohort study of patients under 3 years of age (n=85) undergoing LDLT for biliary atresia using PV interposition grafts.
Iatrogenic intracranial venous hypertension treated with intracranial venous stenting: illustrative case.
J Neurosurg Case Lessons
March 2025
Department of Neurosurgery, Tufts Medical Center, Boston, Massachusetts.
Background: Venous sinus injury resulting in thrombosis is a possible complication of skull base surgery and neck dissection. Although usually asymptomatic, sinus thrombosis can obstruct the dominant cranial venous outflow pathways, leading to a cycle of increased intracranial pressure secondary to venous congestion, which further compresses the remaining sinuses in a positive feedback loop. This can present with symptoms resembling idiopathic intracranial hypertension.
View Article and Find Full Text PDFRevascularization Strategies for Multivessel Disease in Acute Coronary Syndrome: Network Meta-analysis.
J Soc Cardiovasc Angiogr Interv
January 2025
Cardiovascular Institute, Detroit Medical Center, Wayne State University, Detroit, Michigan.
Background: The optimal revascularization strategy for patients with acute coronary syndrome (ACS) and multivessel disease (MVD) remains debated. This study compares the efficacy and safety of different revascularization strategies in these patients.
Methods: We included 20 studies comparing staged, complete, and culprit-only (CO) revascularization strategies in patients with ACS and MVD.
Percutaneous Coronary Treatment With Bioadaptor Implant vs Drug-Eluting Stent: 2-Year Outcomes From BIOADAPTOR RCT.
JACC Cardiovasc Interv
February 2025
Interventional Cardiology, ZAS Cardiovascular Center Middelheim, Antwerp, Belgium.
Background: The sirolimus-eluting bioadaptor is a novel coronary implant that unlocks, separates, and maintains dynamic support of the vessel at the lesion site 6 months after percutaneous coronary intervention when the polymer coating covering the helical strands resorbs. This enables the bioadaptor to maintain the established flow lumen and to restore hemodynamic modulation of the artery, including cyclic pulsatility, vasomotion, and adaptive remodeling.
Objectives: The purpose of this study was to report the first randomized clinical evidence of the DynamX bioadaptor implant through 2 years compared with the Resolute Onyx contemporary drug-eluting stent.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!